Authors: Naresh Kumar
Abstract: Artificial intelligence (AI) is reshaping drug development pipelines across the pharmaceutical industry, driving innovation, reducing costs, and shortening time-to-market for new therapies. This paper analyzes the impact of AI from a business perspective, focusing on how pharmaceutical companies and biotech startups leverage AI technologies to optimize discovery, preclinical research, clinical trials, and regulatory processes. The integration of AI not only enhances scientific outcomes but also transforms business models, investment strategies, and competitive dynamics. Challenges such as data governance, regulatory compliance, and workforce adaptation are discussed alongside strategic recommendations for successful AI adoption. This comprehensive analysis highlights how AI-enabled drug development can provide sustainable business value, foster industry disruption, and ultimately improve patient care worldwide.
DOI: http://doi.org/10.61137/ijsret.vol.8.issue6.565
